Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D09NBH
|
|||
| Former ID |
DIB012864
|
|||
| Drug Name |
ICT-121
|
|||
| Drug Type |
Vaccine
|
|||
| Indication | Recurrent glioblastoma [ICD-11: 2A00.00; ICD-10: C71] | Phase 1 | [1], [2], [3], [4] | |
| Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C76-C80; ICD-9: 140-229] | Phase 1 | [5] | ||
| Company |
Immunocellular therapeutics
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Prominin-1 (PROM1) | Target Info | . | [6] |
| KEGG Pathway | Transcriptional misregulation in cancer | |||
| WikiPathways | Extracellular vesicle-mediated signaling in recipient cells | |||
| Hair Follicle Development: Cytodifferentiation (Part 3 of 3) | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 3 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 4 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 5 | ClinicalTrials.gov (NCT02049489) A Study of ICT-121 Dendritic Cell Vaccine in Recurrent Glioblastoma. U.S. National Institutes of Health. | |||
| REF 6 | Immunotargeting of cancer stem cells. Contemp Oncol (Pozn) 2015; 19(1A): A52-A59. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.